Drawing for ULTRASCAPE

USPTO serial 79271337

ULTRASCAPE

Reviewed by CopyMark Law Group

Reg. 6004774Status 709
Filing date
Status date
Registration date
Mar 10, 2020
Examiner
SEVERSON, JUSTIN
Law office
PUBLICATION AND ISSUE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with ULTRASCAPE?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Goods and services

ClassDescriptionStatusFirst use
042Laboratory research services in the field of biotechnology; laboratory research services in the field of immune profiling; laboratory research services in the field of vaccines; laboratory research services in the field of immunotherapy; laboratory research services in the field of immunotherapy products; laboratory research services relating to vaccines for use in the field of immunotherapy; laboratory research services in the field of vaccines, namely, immunotherapies for the treatment of infectious diseases and cancer; laboratory research services, namely, probing for multiple T cell specificities for identification of tumor antigen-specific T cells for the treatment of cancer; laboratory research services, namely, probing for multiple T cell specificities for identification of viral antigen-specific T cells in the field of infectious diseases; laboratory research services, namely, phenotypic and functional T cell and/or other immune cells profiling for use in the field of immunotherapy; laboratory research services, namely, analysis by time-of-flight mass cytometry; laboratory research services, namely, analysis by flow cytometry; laboratory research services in the field of biomarker discovery; clinical research services for determining a response to treatment for patient stratification via biomarkers, namely, determining the presence of biomarkers in patient samples; laboratory research services, namely, characterization of biomarkers, namely, development and evaluation of biochemical, biological or analytical assays to quantify biomarkers and surrogate markers for the identification of patients and the treatment efficacy or prevention of diseases, disorders and conditions associated with the immune systemSECTION 71 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Sep 25, 2026C71TCANCELLED SECTION 71—
May 8, 2020GPNXNOTIFICATION PROCESSED BY IB—
Apr 22, 2020FICSFINAL DISPOSITION NOTICE SENT TO IB—
Apr 22, 2020FIMPFINAL DISPOSITION PROCESSED—
Apr 9, 2020GPARGRANT OF PROTECTION CREATED, TO BE SENT TO IB—
Mar 10, 2020R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jan 4, 2020GPNXNOTIFICATION PROCESSED BY IB—
Dec 24, 2019PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Dec 18, 2019OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Dec 18, 2019OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Dec 4, 2019NPUBNOTICE OF PUBLICATION—
Nov 21, 2019CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Nov 19, 2019MAFRAPPLICATION FILING RECEIPT MAILED—
Nov 13, 2019DOCKASSIGNED TO EXAMINER—
Nov 13, 2019NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Nov 7, 2019REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance